Results 1 to 10 of about 1,853,915 (311)

ZNF561 antisense RNA 1 contributes to angiogenesis in hepatocellular carcinoma through upregulation of platelet-derived growth Factor-D

Chinese Journal of Physiology, 2022
Hepatocellular carcinoma is a common malignant tumor with high recurrence rate. Long non-coding RNA (lncRNA) ZNF561 antisense RNA 1 (ZNF561-AS1) functions as an oncogenic lncRNA to promote the tumorigenesis of colorectal cancer. The role of ZNF561-AS1 in
Jihu Zheng, Zijian Guo, Zhanchao Wen, Huikang Chen   +3 more
doaj   +1 more source

The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. [PDF]

, 2011
Encapsulation of drugs within nanocarriers that selectively target malignant cells promises to mitigate side effects of conventional chemotherapy and to enable delivery of the unique drug combinations needed for personalized medicine.
Ashley, Carlee E, Brinker, C Jeffrey, Brown, Page A, Carnes, Eric C, Carroll, Nick J, Carter, Mark B, Chackerian, Bryce, Dunphy, Darren R, Durfee, Paul N, Evans, Deborah G, Hanna, Tracey N, Jiang, Xingmao, Liu, Juewen, Padilla, David, Parikh, Atul N, Peabody, David S, Petsev, Dimiter N, Phillips, Brandy, Phillips, Genevieve K, Wharton, Walker, Willman, Cheryl L   +20 more
core   +2 more sources

hsa_circ_0006916 promotes hepatocellular carcinoma progression by activating the miR-337-3p/STAT3 axis

Cellular & Molecular Biology Letters, 2020
Background Circular RNAs (circRNAs) are thought to be involved in the development of various malignancies. The expression and function of hsa_circ_0006916, a newly identified circRNA, in hepatocellular carcinoma remain unclear.
Xiao-Yong Zhou, Hui Yang, Yang-Qiu Bai, Xiu-Ling Li, Shuang-Yin Han, Bing-Xi Zhou   +5 more
doaj   +1 more source

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma [PDF]

, 2016
BACKGROUND: Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with ...
Benvegnu', Luisa, Biasini, Elisabetta, Borzio, Franco, Cabibbo, Giuseppe, Caturelli, Eugenio, Ciccarese, Francesca, Cillo, Umberto, Di Marco, Mariella, Farinati, Fabio, Felder, Martina, Foschi, Francesco Giuseppe, Frigo, Anna Chiara, Gasbarrini, Antonio, Giacomin, Anna, Giannini, Edoardo G., Huo, Teh La, Lee, Yun Hsuan, Masotto, Alberto, Morisco, Filomena, Pawlik, Timothy M., Piscaglia, Fabio, Rapaccini, Gian Lodovico, Sacco, Rodolfo, Spolverato, Gaya, Svegliati Baroni, Gianluca, Trevisani, Franco, Virdone, Roberto, Vitale, Alessandro, Zoli, Marco   +28 more
core   +4 more sources

Basic and Clinical Research Progress of Immunotherapy for Hepatocellular Carcinoma

Zhongliu Fangzhi Yanjiu, 2023
Primary liver cancer, especially hepatocellular carcinoma, poses a serious threat to the life and health of the Chinese people. Given the insidious onset of liver cancer, less than 30% of hepatocellular carcinoma patients are considered for radical ...
ZHANG Zechuan, SUN Beicheng
doaj   +1 more source

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

Liver Cancer, 2021
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH ...
M. Kudo, Y. Kawamura, K. Hasegawa, R. Tateishi, K. Kariyama, S. Shiina, H. Toyoda, Y. Imai, A. Hiraoka, M. Ikeda, N. Izumi, M. Moriguchi, S. Ogasawara, Y. Minami, K. Ueshima, T. Murakami, S. Miyayama, O. Nakashima, H. Yano, M. Sakamoto, E. Hatano, M. Shimada, N. Kokudo, S. Mochida, T. Takehara   +24 more
semanticscholar   +1 more source

Sorafenib in advanced hepatocellular carcinoma.

New England Journal of Medicine, 2008
BACKGROUND No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived ...
G. Spinzi, S. Paggi
semanticscholar   +2 more sources

Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. [PDF]

, 2017
BACKGROUND & AIM: concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following directly acting antiviral (DAA) therapy in cirrhotic patients with a prior complete oncological response have been raised. Data regarding the impact of
Angeli, Paolo, Burra, Patrizia, Cillo, Umberto, Farinati, Fabio, Ferrarese, Alberto, Forton, Dm, Franceschet, E, Gambato, M, Germani, Giacomo, Mescoli, Claudia, Romano, Antonietta, Rugge, Massimo, Russo, FRANCESCO PAOLO, Senzolo, Marco, Shalaby, S, Vitale, A, Zanetto, Alberto   +16 more
core   +1 more source

CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis

Journal of Experimental & Clinical Cancer Research, 2019
Background CDK5, an atypical member of the CDK family, play a significant role in the tumorigenesis of multiple organ, but CDK5 and its substrates in genesis and development of HCC is still unclear.
Fuqiang Wang, Wenxing Zhao, Yuehong Gao, Jiechao Zhou, Huifang Li, Guanyun Zhang, Dong Guo, Chengrong Xie, Jie Li, Zhenyu Yin, Jie Zhang   +10 more
doaj   +1 more source

Epidemiology of Hepatocellular Carcinoma

Hepatology, 2020
Liver cancer is a major contributor to the worldwide cancer burden. Incidence rates of this disease have increased in many countries in recent decades.
K. McGlynn, J. Petrick, H. El‐Serag
semanticscholar   +1 more source